Market Closed -
Other stock markets
|
Pre-market 07:00:19 am | |||
417.3 USD | -0.27% | 419.5 | +0.52% |
Mar. 21 | Vertex Pharmaceuticals Gets FDA Approval for VX-407's Investigational New Drug Application to Treat Kidney Disease | MT |
Mar. 21 | Vertex Gets FDA OK to Study VX-407 in Genetic Kidney Disease | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.56% | 108B | |
+10.02% | 104B | |
+8.15% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B | |
-5.38% | 10.36B |
- Stock
- Equities
- Stock Vertex Pharmaceuticals Incorporated - Nasdaq
- News Vertex Pharmaceuticals Incorporated
- Vertex Secures European Commission's Approval for Kaftrio With Ivacaftor as Treatment for Cystic Fibrosis in Children